Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma

References

• Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415–21.
   PubMed Web of Science ®Google Scholar
• Torkamani A, Verkhivker G, Schork NJ. Cancer driver mutations in protein kinase genes. Cancer Lett 2009; 281:117–27.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507–16. PMID:21639808.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645–52. PMID:11870241.
   PubMed Web of Science ®Google Scholar
• Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. EMBO J 2013; 32:194–203. PMID:23258224.
   PubMed Web of Science ®Google Scholar
• Reinbold CJ, Malarkannan S. Recognition of allo-peptide is governed by novel anchor imposition and limited variations in TCR contact residues. Mol Immunol 2008; 45:1318–26. PMID:17981332.
   PubMed Web of Science ®Google Scholar
• Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wolfel C, Huber C, Wolfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005; 102:16013–8. PMID:16247014.
   PubMed Web of Science ®Google Scholar
• Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, Behjati S, Velds A, Hilkmann H, Atmioui DE, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2015; 21:81–5. PMID:25531942.
   PubMed Web of Science ®Google Scholar
• Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res 2014; 20:3401–10. PMID:24987109.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19:747–52; PMID:23644516; https://doi.org/10.1038/nm.3161
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641–5; PMID:24812403; https://doi.org/10.1126/science.1251102
   PubMed Web of Science ®Google Scholar
• Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, Castellarin M, Twumasi-Boateng K, Watson PH, Holt RA, et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res 2014; 20:1125–34; PMID:24323902; https://doi.org/10.1158/1078-0432.CCR-13-2147
   PubMed Web of Science ®Google Scholar
• Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015; 350:1387–90; PMID:26516200; https://doi.org/10.1126/science.aad1253
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med 2016; 375:2255–62; PMID:27959684; https://doi.org/10.1056/NEJMoa1609279
   PubMed Web of Science ®Google Scholar
• Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, Boschen ML, Lund-Johansen F, Olweus J, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 2016; 352:1337–41; PMID:27198675; https://doi.org/10.1126/science.aaf2288
   PubMed Web of Science ®Google Scholar
• Sharkey MS, Lizee G, Gonzales MI, Patel S, Topalian SL. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 2004; 64:1595–9; PMID:14996715; https://doi.org/10.1158/0008-5472.CAN-03-3231
   PubMed Web of Science ®Google Scholar
• Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101:2290–6; PMID:9593785; https://doi.org/10.1172/JCI488
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Sedgwick CG, Shahid A, Zong Z, Brumme ZL, Yu S, Liu L, Kroeger DR, Treon SP, Connors JM, et al. Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clin Cancer Res 2016; 22:2226-36; PMID:26631611 https://doi.org/10.1158/1078-0432.CCR-15-2023
   PubMed Web of Science ®Google Scholar
• Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437:141–6; PMID:16136144; https://doi.org/10.1038/nature03954
   PubMed Web of Science ®Google Scholar
• Watters TM, Kenny EF, O'Neill LA. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 2007; 85:411–9; PMID:17667936; https://doi.org/10.1038/sj.icb.7100095
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470:115–9; PMID:21179087; https://doi.org/10.1038/nature09671
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012; 367:826–33; PMID:22931316; https://doi.org/10.1056/NEJMoa1200710
   PubMed Web of Science ®Google Scholar
• Jimenez C, Sebastian E, Chillon MC, Giraldo P, Mariano Hernandez J, Escalante F, Gonzalez-Lopez TJ, Aguilera C, de Coca AG, Murillo I, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia. Leukemia 2013; 27:1722–8; PMID:23446312; https://doi.org/10.1038/leu.2013.62
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 2011; 122:791–2; PMID:22020631; https://doi.org/10.1007/s00401-011-0891-2
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis G, Jares P, Bea S, Gonzalez-Diaz M, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475:101–5; PMID:21642962; https://doi.org/10.1038/nature10113
   PubMed Web of Science ®Google Scholar
• Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, Corso A, Orlandi E, Bonfichi M, Gotti M, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 2013; 121:2522–8; PMID:23355535; https://doi.org/10.1182/blood-2012-09-457101
   PubMed Web of Science ®Google Scholar
• Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013; 121:2051–8; PMID:23321251; https://doi.org/10.1182/blood-2012-09-454355
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 2016; 42:279–90; PMID:26111727; https://doi.org/10.1111/nan.12259
   PubMed Web of Science ®Google Scholar
• Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012; 106:243–7; PMID:22187039; https://doi.org/10.1038/bjc.2011.551
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42:181–5; PMID:20081860; https://doi.org/10.1038/ng.518
   PubMed Web of Science ®Google Scholar
• Bodor C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013; 122:3165–8; PMID:24052547; https://doi.org/10.1182/blood-2013-04-496893
   PubMed Web of Science ®Google Scholar
• Fucikova J, Rozkova D, Ulcova H, Budinsky V, Sochorova K, Pokorna K, Bartunkova J, Spisek R. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med 2011; 9:223; PMID:22208910; https://doi.org/10.1186/1479-5876-9-223
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26:332–42; PMID:12843795; https://doi.org/10.1097/00002371-200307000-00005
   PubMed Web of Science ®Google Scholar
• Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; PMID:25837513; https://doi.org/10.1126/science.aaa3828
   PubMed Web of Science ®Google Scholar
• Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, Castermans E, Thor Straten P, Blank C, Haanen JB, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009; 6:520–6; PMID:19543285; https://doi.org/10.1038/nmeth.1345
   PubMed Web of Science ®Google Scholar
• Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 2016; 32:511–7; PMID:26515819; https://doi.org/10.1093/bioinformatics/btv639
   PubMed Web of Science ®Google Scholar
• Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S, Brunak S, Lund O. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003; 12:1007–17; PMID:12717023; https://doi.org/10.1110/ps.0239403
   PubMed Web of Science ®Google Scholar
• Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009; 10:296.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007; 8:238; PMID:17608956; https://doi.org/10.1186/1471-2105-8-238
   PubMed Web of Science ®Google Scholar
• van Buuren MM, Calis JJ, Schumacher TN. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology 2014; 3:e28836; PMID:25083320; https://doi.org/10.4161/onci.28836
   PubMed Web of Science ®Google Scholar
• Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res 2014; 2:522–9; PMID:24894089; https://doi.org/10.1158/2326-6066.CIR-13-0227
   PubMed Web of Science ®Google Scholar
• Calis JJ, Reinink P, Keller C, Kloetzel PM, Kesmir C. Role of peptide processing predictions in T cell epitope identification: contribution of different prediction programs. Immunogenetics 2015; 67:85–93; PMID:25475908; https://doi.org/10.1007/s00251-014-0815-0
   PubMed Web of Science ®Google Scholar
• Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP, Blanchard T, McMahon D, Sidney J, Sette A, et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 2014; 211:2231–48; PMID:25245761; https://doi.org/10.1084/jem.20141308
   PubMed Web of Science ®Google Scholar
• Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 1997; 182:137–51; PMID:9514698; https://doi.org/10.1006/cimm.1997.1224
   PubMed Web of Science ®Google Scholar
• Bergmann-Leitner ES, Kantor JA, Shupert WL, Schlom J, Abrams SI. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. Cell Immunol 1998; 187:103–16; PMID:9732698; https://doi.org/10.1006/cimm.1998.1325
   PubMed Web of Science ®Google Scholar
• Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011; 39:D913–9; PMID:21062830; https://doi.org/10.1093/nar/gkq1128
   PubMed Web of Science ®Google Scholar
• Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319:1676–9; PMID:18323416; https://doi.org/10.1126/science.1153629
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298–303; PMID:21796119; https://doi.org/10.1038/nature10351
   PubMed Web of Science ®Google Scholar
• Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014; 46:176–81; PMID:24362818; https://doi.org/10.1038/ng.2856
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471:189–95; PMID:21390126; https://doi.org/10.1038/nature09730
   PubMed Web of Science ®Google Scholar
• Yildiz M, Li H, Bernard D, Amin NA, Ouillette P, Jones S, Saiya-Cork K, Parkin B, Jacobi K, Shedden K, et al. Activating STAT6 mutations in follicular lymphoma. Blood 2015; 125:668-79; https://doi.org/10.1182/blood-2014-06-582650
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, Boegel S, Schrors B, Vascotto F, Castle JC, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520:692–6; PMID:25901682; https://doi.org/10.1038/nature14426
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 2015; 125:3981–91; PMID:26389673; https://doi.org/10.1172/JCI82416
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126–9; PMID:16946036; https://doi.org/10.1126/science.1129003
   PubMed Web of Science ®Google Scholar